Hunter Smith has been our Chief Financial Officer since August 2017, and served as our interim Chief Executive Officer from March to July 2020. Since joining Rhythm, Hunter led the company in an initial public offering that netted the Company $125 million, as well as two follow-on public offerings that netted approximately $346 million. As a member of the management team, Hunter has played a critical role in charting Rhythm’s corporate strategy and enabling its growth and development. He has over 25 years’ experience in global finance and management roles across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. He joined Rhythm from Celgene Corporation, where he served as Vice President, Finance and Chief Financial Officer of the Company’s Inflammation and Immunology Business Unit. In this role, Hunter provided finance leadership for the global launch of Otezla®, co-led the integration of Receptos, Inc. following its acquisition by Celgene, and led global business planning and analysis for operations in over 16 countries. Before joining Celgene, Hunter worked for fourteen years in roles of increasing responsibility at Bunge Limited, including Director of Investor Relations, Chief Financial Officer–Asia, Chief Risk Officer, Corporate Treasurer, and Chief Financial Officer of Bunge’s Sugar and Bioenergy Segment. He holds an MBA in Finance from NYU’s Stern School of Business and a BA in History, with honors, from Northwestern University. Hunter serves on the Board of Directors of Aeglea BioTherapeutics, Inc., and he previously served as an Independent Director of Genessee & Wyoming Inc. and as a member of the Compensation and Governance Committees, from 2015 until its acquisition by Brookfield Infrastructure Partners in December 2019.
What is Hunter C. Smith's net worth?
The estimated net worth of Hunter C. Smith is at least $5.86 million as of February 19th, 2025. Mr. Smith owns 109,929 shares of Rhythm Pharmaceuticals stock worth more than $5,861,414 as of February 27th. This net worth approximation does not reflect any other assets that Mr. Smith may own. Additionally, Mr. Smith receives an annual salary of $757,320.00 as CFO at Rhythm Pharmaceuticals. Learn More about Hunter C. Smith's net worth.
How old is Hunter C. Smith?
Mr. Smith is currently 55 years old. There are 6 older executives and no younger executives at Rhythm Pharmaceuticals. The oldest executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who is 70 years old. Learn More on Hunter C. Smith's age.
What is Hunter C. Smith's salary?
As the CFO of Rhythm Pharmaceuticals, Inc., Mr. Smith earns $757,320.00 per year. There are 2 executives that earn more than Mr. Smith. The highest earning executive at Rhythm Pharmaceuticals is Dr. David P. Meeker M.D., Chairman, President & CEO, who commands a salary of $1,350,000.00 per year. Learn More on Hunter C. Smith's salary.
How do I contact Hunter C. Smith?
The corporate mailing address for Mr. Smith and other Rhythm Pharmaceuticals executives is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. Rhythm Pharmaceuticals can also be reached via phone at (857) 264-4280 and via email at hannah.deresiewicz@sternir.com. Learn More on Hunter C. Smith's contact information.
Has Hunter C. Smith been buying or selling shares of Rhythm Pharmaceuticals?
During the past quarter, Hunter C. Smith has sold $300,998.80 in Rhythm Pharmaceuticals stock. Most recently, Hunter C. Smith sold 2,215 shares of the business's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a transaction totalling $126,742.30. Following the completion of the sale, the chief financial officer now directly owns 109,929 shares of the company's stock, valued at $6,290,137.38. Learn More on Hunter C. Smith's trading history.
Who are Rhythm Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Rhythm Pharmaceuticals?
In the last twelve months, insiders at the sold shares 31 times. They sold a total of 344,246 shares worth more than $17,662,359.40. The most recent insider tranaction occured on February, 19th when CFO Hunter C Smith sold 2,215 shares worth more than $126,742.30. Insiders at Rhythm Pharmaceuticals own 5.6% of the company.
Learn More about insider trades at Rhythm Pharmaceuticals. Information on this page was last updated on 2/19/2025.